Table 1 Baseline characteristics of patients in the PLATO study, by treatment group*[7]
From: Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
Characteristic | Ticagrelor group (N = 9333) | Clopidogrel group (N = 9291) |
|---|---|---|
Age — median (range) | 62.0 (19–97) | 62.0 (21–94) |
Female sex — no. (%) | 2655 (28.4) | 2633 (28.3) |
BMI — median (range) | 27 (13–68) | 27 (13–70) |
Cardiovascular risk factor — no./total no. (%) |  |  |
Habitual smoker | 3360 (36.0) | 3318 (35.7) |
Hypertension | 6139 (65.8) | 6044 (65.1) |
Dyslipidemia | 4347 (46.6) | 4342 (46.7) |
Diabetes mellitus | 2326 (24.9) | 2336 (25.1) |
Other medical history — no./total no. (%) |  |  |
MI | 1900 (20.4) | 1924 (20.7) |
Percutaneous coronary intervention | 1272 (13.6) | 1220 (13.1) |
Congestive heart failure | 513 (5.5) | 537 (5.8) |
Final diagnosis of ACS — no./total no. (%) |  |  |
ST-elevation MI | 3496 (37.5) | 3530 (38.0) |
Non–ST-elevation MI | 4005 (42.9) | 3950 (42.5) |
Unstable angina | 1549 (16.6) | 1563 (16.8) |
Other diagnosis or missing data | 283 (3.0) | 248 (2.7) |